Cargando…

RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy

Clinically, temozolomide (TMZ) is widely used in glioblastoma (GBM) treatment. However, the toxicity of TMZ may influence the quality of patient life. Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary. Aurora-A is widely expressed in GBM and correlated with po...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Jing, Wang, Fangfang, Mu, Dezhi, Qu, Yi, Luo, Rong, Wang, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228570/
https://www.ncbi.nlm.nih.gov/pubmed/28105161
http://dx.doi.org/10.3892/ol.2016.5261
_version_ 1782493970779078656
author Gan, Jing
Wang, Fangfang
Mu, Dezhi
Qu, Yi
Luo, Rong
Wang, Qiu
author_facet Gan, Jing
Wang, Fangfang
Mu, Dezhi
Qu, Yi
Luo, Rong
Wang, Qiu
author_sort Gan, Jing
collection PubMed
description Clinically, temozolomide (TMZ) is widely used in glioblastoma (GBM) treatment. However, the toxicity of TMZ may influence the quality of patient life. Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary. Aurora-A is widely expressed in GBM and correlated with poor prognosis. It has been proven to be an effective target for gene therapy and chemotherapy. In the present study, short hairpin (sh)RNA targeting Aurora-A was employed to knockdown Aurora-A expression in GBM cells. Cell Counting Kit-8 assays, flow cytometry, colony formation assays, invasion assays and tube formation assays were used to determine the effects of Aurora-A knockdown when combined with TMZ treatment. A U251 subcutaneous cancer model was established to evaluate the efficacy of combined therapy. The results of the present study indicated that the proliferation, colony formation, invasion and angiogenesis of GBM cells were significantly inhibited by combined therapy when compared with TMZ treatment alone. In vivo results demonstrated that knockdown of Aurora-A significantly (P=0.0084) sensitizes GBM cells to TMZ chemotherapy. The results of the present study demonstrated that knockdown of Aurora-A in GBM cells enhances TMZ sensitivity in vitro and in vivo. Therefore, Aurora-A knockdown may be a novel treatment option for decreasing TMZ toxicity and improving patient quality of life.
format Online
Article
Text
id pubmed-5228570
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-52285702017-01-19 RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy Gan, Jing Wang, Fangfang Mu, Dezhi Qu, Yi Luo, Rong Wang, Qiu Oncol Lett Articles Clinically, temozolomide (TMZ) is widely used in glioblastoma (GBM) treatment. However, the toxicity of TMZ may influence the quality of patient life. Thus, novel treatment options for sensitizing GBM cells to TMZ chemotherapy are necessary. Aurora-A is widely expressed in GBM and correlated with poor prognosis. It has been proven to be an effective target for gene therapy and chemotherapy. In the present study, short hairpin (sh)RNA targeting Aurora-A was employed to knockdown Aurora-A expression in GBM cells. Cell Counting Kit-8 assays, flow cytometry, colony formation assays, invasion assays and tube formation assays were used to determine the effects of Aurora-A knockdown when combined with TMZ treatment. A U251 subcutaneous cancer model was established to evaluate the efficacy of combined therapy. The results of the present study indicated that the proliferation, colony formation, invasion and angiogenesis of GBM cells were significantly inhibited by combined therapy when compared with TMZ treatment alone. In vivo results demonstrated that knockdown of Aurora-A significantly (P=0.0084) sensitizes GBM cells to TMZ chemotherapy. The results of the present study demonstrated that knockdown of Aurora-A in GBM cells enhances TMZ sensitivity in vitro and in vivo. Therefore, Aurora-A knockdown may be a novel treatment option for decreasing TMZ toxicity and improving patient quality of life. D.A. Spandidos 2016-12 2016-10-14 /pmc/articles/PMC5228570/ /pubmed/28105161 http://dx.doi.org/10.3892/ol.2016.5261 Text en Copyright: © Gan et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Gan, Jing
Wang, Fangfang
Mu, Dezhi
Qu, Yi
Luo, Rong
Wang, Qiu
RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title_full RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title_fullStr RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title_full_unstemmed RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title_short RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy
title_sort rna interference targeting aurora-a sensitizes glioblastoma cells to temozolomide chemotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228570/
https://www.ncbi.nlm.nih.gov/pubmed/28105161
http://dx.doi.org/10.3892/ol.2016.5261
work_keys_str_mv AT ganjing rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy
AT wangfangfang rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy
AT mudezhi rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy
AT quyi rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy
AT luorong rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy
AT wangqiu rnainterferencetargetingauroraasensitizesglioblastomacellstotemozolomidechemotherapy